Aurinia Pharmaceuticals Inc. (AUPH)Healthcare | Biotechnology | Edmonton, Canada | NasdaqGM
16.29 USD
-0.18
(-1.123%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 16.35 +0.06 (0.368%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:59 a.m. EDT
The immediate outlook is bullish, driven by a confluence of strong recent price momentum and aggressive speculative positioning. The stock has rallied significantly over the last year, breaking out above key moving averages, while the CEO's recent large purchase signals insider confidence. Options flow confirms this sentiment, with traders buying calls at strikes above the current price, betting on further appreciation. However, the lack of a dividend and the inherent risks of the biotech sector prevent a top-tier long-term rating. While the business shows improving fundamentals with positive revenue growth and a fortress-like balance sheet relative to debt, the absence of income generation and the binary nature of drug development keep the long-term assessment in the upper-middle tier rather than exceptional. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.041181 |
| MSTL | 0.045022 |
| AutoTheta | 0.045404 |
| AutoETS | 0.046830 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 56% |
| H-stat | 0.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.015 |
| Excess Kurtosis | 0.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.431 |
| Revenue per Share | 2.368 |
| Market Cap | 2,167,403,776 |
| Trailing P/E | 7.21 |
| Forward P/E | 15.27 |
| Beta | 1.40 |
| Profit Margins | 100.84% |
| Website | https://www.auriniapharma.com |
As of Aug. 22, 2026, 4:59 a.m. EDT: Speculators are positioning for a moderate upside move in the near term, evidenced by heavy open interest in out-of-the-money calls (particularly the $20 strike) relative to puts. However, the long-dated options chain reveals a distinct 'put wall' at lower strikes ($10-$15 range) with significant volume and open interest, suggesting a floor or hedging demand against a deeper decline. Implied volatility is elevated for near-term expiration, indicating anticipation of earnings or catalyst-driven movement.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4105308 |
| Address1 | #140, 14315 – 118 Avenue |
| All Time High | 33.972 |
| All Time Low | 1.41 |
| Ask | 17.28 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,116,300 |
| Average Daily Volume3 Month | 1,463,585 |
| Average Volume | 1,463,585 |
| Average Volume10Days | 1,116,300 |
| Beta | 1.403 |
| Bid | 12.84 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 4.626 |
| City | Edmonton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.29 |
| Current Ratio | 5.419 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 16.469 |
| Day Low | 16.26 |
| Debt To Equity | 10.431 |
| Display Name | Aurinia Pharmaceuticals |
| Earnings Call Timestamp End | 1,772,112,600 |
| Earnings Call Timestamp Start | 1,772,112,600 |
| Earnings Growth | 0.755 |
| Earnings Quarterly Growth | 0.739 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | 179,826,000 |
| Ebitda Margins | 0.57728 |
| Enterprise To Ebitda | 9.946 |
| Enterprise To Revenue | 5.741 |
| Enterprise Value | 1,788,516,480 |
| Eps Current Year | 0.944 |
| Eps Forward | 1.06667 |
| Eps Trailing Twelve Months | 2.26 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 250 708 4345 |
| Fifty Day Average | 15.9911 |
| Fifty Day Average Change | 0.2989006 |
| Fifty Day Average Change Percent | 0.018691685 |
| Fifty Two Week Change Percent | 41.05308 |
| Fifty Two Week High | 19.25 |
| Fifty Two Week High Change | -2.959999 |
| Fifty Two Week High Change Percent | -0.15376619 |
| Fifty Two Week Low | 10.34 |
| Fifty Two Week Low Change | 5.950001 |
| Fifty Two Week Low Change Percent | 0.5754353 |
| Fifty Two Week Range | 10.34 - 19.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,409,751,000,000 |
| Float Shares | 128,675,115 |
| Forward Eps | 1.06667 |
| Forward P E | 15.271829 |
| Free Cashflow | 147,817,120 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 128 |
| Fullday Change | -0.184999 |
| Fullday Change Percent | -1.12291 |
| Fullday Price | 16.35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.77884 |
| Gross Profits | 242,614,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06626 |
| Held Percent Institutions | 0.60409 |
| Implied Shares Outstanding | 133,051,168 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.isotechnika.com/for_investors/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada. |
| Long Name | Aurinia Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 2,167,403,776 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_882669 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 314,113,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,192,017,992 |
| Number Of Analyst Opinions | 7 |
| Open | 16.44 |
| Operating Cashflow | 175,243,008 |
| Operating Margins | 0.55685 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 250 744 2487 |
| Post Market Change | 0.059999466 |
| Post Market Change Percent | 0.36832082 |
| Post Market Price | 16.35 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 16.475 |
| Price Eps Current Year | 17.256357 |
| Price Hint | 2 |
| Price To Book | 3.521401 |
| Price To Sales Trailing12 Months | 6.957801 |
| Profit Margins | 1.0083699 |
| Quick Ratio | 4.857 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.184999 |
| Regular Market Change Percent | -1.12291 |
| Regular Market Day High | 16.469 |
| Regular Market Day Low | 16.26 |
| Regular Market Day Range | 16.26 - 16.469 |
| Regular Market Open | 16.44 |
| Regular Market Previous Close | 16.475 |
| Regular Market Price | 16.29 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 630,566 |
| Return On Assets | 0.15489 |
| Return On Equity | 0.66117996 |
| Revenue Growth | 0.189 |
| Revenue Per Share | 2.368 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 133,051,168 |
| Shares Percent Shares Out | 0.0723 |
| Shares Short | 9,615,436 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 9,714,642 |
| Short Name | Aurinia Pharmaceuticals Inc |
| Short Percent Of Float | 0.0798 |
| Short Ratio | 8.77 |
| Source Interval | 15 |
| State | AB |
| Symbol | AUPH |
| Target High Price | 21.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 17.85714 |
| Target Median Price | 17.0 |
| Total Cash | 443,023,008 |
| Total Cash Per Share | 3.33 |
| Total Debt | 64,136,000 |
| Total Revenue | 311,507,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.26 |
| Trailing P E | 7.207965 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.46715 |
| Two Hundred Day Average Change | 0.8228512 |
| Two Hundred Day Average Change Percent | 0.053199925 |
| Type Disp | Equity |
| Volume | 630,566 |
| Website | https://www.auriniapharma.com |
| Zip | T5L 4S6 |